Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European …

In less than 10 years, the prognosis of chronic myeloid leukaemia has changed from that of
a fatal disease to a disorder amenable simply to lifelong oral medication and compatible …

Dasatinib is a potent BCR-ABL inhibitor effective in chronic myeloid leukemia and Ph+ acute
lymphoblastic leukemia (ALL) resistant/intolerant to imatinib. In the GIMEMA LAL1205 …

Chronic Myeloid Leukemia (CML) is a clonal disease characterized by the presence of the
Philadelphia (Ph+) chromosome and its oncogenic product, BCR-ABL, a constitutively active …

Blast crisis (BC) remains the major challenge in the management of chronic myeloid
leukemia (CML). It is now generally accepted that BC is the consequence of continued BCR …

Few neoplastic diseases have undergone a transformation in a relatively short period like
chronic myeloid leukemia (CML) has in the last few years. In 1960, CML was the first cancer …

Dasatinib is a BCR-ABL inhibitor with 325-fold higher potency than imatinib against
unmutated BCR-ABL in vitro. Imatinib failure is commonly caused by BCR-ABL mutations …

Management of chronic myeloid leukemia (CML) in advanced phases remains a challenge
also in the era of tyrosine kinase inhibitors (TKIs) treatment. Cytogenetic clonal evolution …

Although imatinib remains the gold standard for first-line treatment of chronic myeloid
leukemia (CML), increasing recognition of imatinib resistance and intolerance has led to the …

Although only 5000 new cases of chronic myeloid leukemia (CML) were seen in the United
States in 2009, this neoplasm continues to make scientific headlines year-after-year …